Clinical Trials Logo

Hereditary Angioedema clinical trials

View clinical trials related to Hereditary Angioedema.

Filter by:

NCT ID: NCT04618211 Completed - Clinical trials for Hereditary Angioedema

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

RAPIDe-1
Start date: February 3, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.

NCT ID: NCT04557319 Completed - Clinical trials for Hereditary Angioedema

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

Start date: March 10, 2020
Phase: Phase 1
Study type: Interventional

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-038.

NCT ID: NCT04428632 Approved for marketing - Clinical trials for Hereditary Angioedema

Oral Berotralstat Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.

NCT ID: NCT04349800 Completed - Clinical trials for Hereditary Angioedema

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Start date: January 4, 2018
Phase: Phase 1
Study type: Interventional

A safety, tolerability, pharmacokinetic and food effect study of KVD900 in healthy volunteers.

NCT ID: NCT04307381 Active, not recruiting - Clinical trials for Hereditary Angioedema

An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema

Start date: April 1, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of extended dosing of donidalorsen administered subcutaneously (SC), with alternative dosing and/or dose frequency with donidalorsen in participants with hereditary angioedema (HAE).

NCT ID: NCT04208412 Completed - Clinical trials for Hereditary Angioedema

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Start date: July 2, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.

NCT ID: NCT04091113 Terminated - Clinical trials for Hereditary Angioedema

Hereditary Angioedema Kininogen Assay

HAEKA
Start date: September 1, 2019
Phase:
Study type: Observational

A multicenter epidemiological observational study aiming to explore the cleaved high-molecular weight kininogen (cHMWK) including identification and characterization of other metabolite/biomarkers in HAE type 1/2 patients

NCT ID: NCT04070326 Completed - Clinical trials for Hereditary Angioedema

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

SPRING
Start date: August 19, 2019
Phase: Phase 3
Study type: Interventional

The main aims of this study are to learn how lanadelumab moves through a child's body and if the children have any medical problems from lanadelumab. Other aims are to learn if prophylactic treatment with lanadelumab reduces the number and severity of HAE attacks in children, how lanadelumab affects the child's body, and if the children develop antibodies to lanadelumab. The study doctors will treat acute HAE attacks according to their standard practice. Participants will receive lanadelumab for up to 52 weeks. When they start treatment, participants will visit their clinic every week for the first 4 weeks. Then, they will visit their clinic every 4 weeks during treatment.

NCT ID: NCT04030598 Completed - Clinical trials for Hereditary Angioedema

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Start date: January 7, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the clinical efficacy, safety, and tolerability of donidalorsen in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of donidalorsen on plasma prekallikrein (PKK) and other relevant biomarkers.

NCT ID: NCT03712228 Completed - Clinical trials for Hereditary Angioedema

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

Start date: October 29, 2018
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.